Western Blotting (WB), Enzyme Immunoassay (EIA), Radioimmunoassay (RIA)
Specificité
Clone RFFVIIIC/8 is a very potent coagulation inhibitor. This antibody recognizes an epitope towards the N-terminus of full length Factor VIII. It also recognises the 210 kDa, 90 kDa and 40 kDa cleavage products. This clone does not cross-react with von Willebrand factor.
Aucune reactivité croisée
Souris, Chien, Rat (Rattus)
Réactivité croisée (Details)
Species reactivity (tested):Human and Pig.
Purification
Affinity Chromatography on Protein G from tissue culture supernatant
ELISA: 1:200 - 1:2000. Western blotting: 1:20 - 1:200. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Concentration
1.0 mg/mL
Buffer
PBS, 0.09 % Sodium Azide
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Conseil sur la manipulation
Avoid repeated freezing and thawing.
Stock
4 °C/-20 °C
Stockage commentaire
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
Human Factor VIII is an essential blood coagulation factor. Whilst circulating in the blood, it is mostly stably complexed to von Willebrand factor. It is activated through cleavage at various sites, dissociates from the complex and interacts with Factor IXa, in the presence of calcium ions and phospholipids, to convert Factor X to the activated Factor Xa, which activates thrombin. Thrombin cleaves fibrinogen into fibrin, which polymerises and crosslinks to form a blood clot. The activated Factor VIII is proteolytically inactivated and cleared from the bloodstream. Defects in Factor VIII cause haemophilia A, a disorder characterised by the body's inability to control blood clotting. This could result in severe blood loss, even with minor injuries.Synonyms: AHF, Antihemophilic factor, F8C, Procoagulant component